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Filamentoustau-positiveproteininclusionsinneuronsandgliaareprominentfeaturesofanumberofneurodegenerativedisorders
termed tauopathies. These inclusions are further characterized by the presence of heat shock proteins (HSPs). The group of small
HSPs, namely, HSP27 and αB-crystallin, interact with the cytoskeleton, bind to nonnative proteins, and prevent their aggregation
after stress. To further investigate their contribution to neurodegenerative diseases, we have analyzed the association of HSP27
with pathological lesions of tauopathies. Microarray and immunoblot analysis revealed that HSP27 is enhanced at the mRNA and
p r o t e i nl e v e l si na ﬀected brains, and that it is associated with astrocytic pathology. The upregulation of HSP27 in tauopathies with
gial pathology implies distinct mechanisms for glial and neuronal cells. This was sustained by cell culture studies, demonstrating
that the small HSPs are speciﬁcally and prominently expressed in unstressed astrocytes and not in neurons and in neurons
remained at a rather low level even after stress situations.
1.Introduction
Filamentous protein inclusions are observed in a number of
neurodegenerative diseases. They contain a cellular protein,
such as α-synuclein or tau, and often a variety of heat shock
proteins (HSPs) and ubiquitin in addition to cytoskeletal
proteins [1–4]. HSPs acting as molecular chaperones refold
damaged proteins and target irreversibly damaged proteins
for degradation to the ubiquitin-proteasome system to
prevent proteotoxic damage. Their presence in cellular inclu-
sions indicates that they were unsuccessfully upregulated in
an attempt to prevent protein denaturation and aggregation.
Furthermore it indicates that stress situations, such as
oxidative stress, heat stress, or stress induced by proteasomal
impairment, contribute to the pathogenesis of the disorders
[3].
Pathological inclusions containing the microtubule-
associated protein tau in its hyperphosphorylated form are
a characteristic hallmark of a class of both sporadic and
familial disorders, termed tauopathies [1, 2, 4]. While in
Alzheimer’s disease (AD) tau aggregates preferentially are
formed in neurons, in frontotemporal dementias, such as
Pick’s disease, progressive supranuclear palsy (PSP), and
corticobasal degeneration (CBD), tau-positive inclusions
are consistent features not only in neurons but also in
glia [5–8]. Neuronal and glial ﬁlamentous lesions in PSP
and CBD are composed of hyperphosphorylated tau with
four microtubule binding repeats, that is, 4R-tau [9].
Tau is a microtubule-binding protein that is abundantly
expressed in the central nervous system. It is important
for microtubule assembly and stability, and in normal
brain is mainly located in axons and not expressed in
healthy astrocytes [10]. Data from our laboratory have
demonstrated that it is also an important constitutent of
the oligodendroglial cytoskeleton [7, 11]. Based on their
cellular origin, in PSP and CBD tau-positive glial inclusions
are classiﬁed as tau-positive astrocytes and oligodendroglial
coiled bodies [8, 9, 12]. Astrocytic inclusions vary among
the diseases; they do not form solid inclusion bodies but
rather exhibit diﬀuse or ﬁbrillary staining patterns. Tufted2 International Journal of Cell Biology
astrocytes and astrocytic plaques are typical for PSP and
CBD, respectively, while tau-positive coiled bodies origi-
nating in oligodendrocytes can be found in both disorders
[4, 12, 13].
The group of small HSPs with molecular weights in
the range of 12–43kDa is closely related [14, 15]. The
best known representatives are αB-crystallin and HSP27,
or its rat analogue HSP25. They are involved in a variety
of cellular processes, particularly interact with cytoskeletal
elements, are stress, inducible, display chaperone function
and eﬀectively bind to nonnative proteins, preventing the
aggregation of proteins after stress [16, 17]. Cultured rat
brain astrocytes constitutively express a high level of HSP25,
w h i c he x e r t sp r o t e c t i v ee ﬀects against a variety of stress
situations, while in oligodendrocytes αB-crystallin seems to
be more important [18, 19]. In AD small HSPs have been
found to be associated with astrocytes in senile plaques
and not with neurons in neuroﬁbrillary tangles [20]. αB-
Crystallinimmunoreactivityseemedtobespeciﬁctodiseases
with glial pathology [5, 21].
To further investigate the contribution of small HSPs to
neurodegenerative diseases, we have analyzed the association
of HSP27 with pathological lesions of PSP and CBD brains.
Furthermore, since distinct pathogenic mechanisms and
stress protein induction in neurons and astrocytes seem to
contribute to tau pathology, we have compared HSP expres-
sion and upregulation in cultured neurons and astrocytes
derived from rat brain. Immunoblot analysis demonstrates
that HSP27 is upregulated in the brains of patients with
PSP and CBD, and found in cell inclusions with astrocytic
morphology. Furthermore, it is more prominently expressed
in cultured astrocytes under normal and stress-induced
conditions than in neurons.
2.MaterialsandMethods
2.1. Materials and Antibodies. Cell culture media were from
Invitrogen (Grand Island, NY).
For Western Blot analysis or immunoﬂuorescence the
following antibodies were used: mAb anti-HSP70 (SPA-810),
mAb anti-HSP/HSC70 (SPA-820), mAb anti-HSP60 (SPA-
806), polyclonal anti-HSP40 (SPA-400), polyclonal anti-
HSP32 (SPA-895), polyclonal anti-HSP25 (SPA-801), poly-
clonal anti-HSP27 (Spa-803), and mAb anti-αB-crystallin
(SPA-222) from StressGen (Victoria, BC, Canada). Poly-
clonal anti-α-tubulin, mAb anti-α-tubulin, and mAb anti-
GFAP were from Sigma (Taufkirchen, Germany). A mixture
of mAbs anti-tau-14 and anti-tau-46 (both diluted 1:500)
recognizing all Tau isoforms independently of phosphoryla-
tion, mAb PHF-1 (1:500) recognizing Tau phosphorylated
at serine residues 396 and 404 and mAb Tau-1 speciﬁc
for nonphosphorylated tau epitope located in amino acid
residues 189–209 were used. The working dilution for
Western Blot analysis was 1:1000 if not mentioned in
parenthesis.
2.2. Sequential Biochemical Fractionation of Brain Tissue.
Brain tissue was obtained from the Center for Neurode-
generative Disease Research and the AD Center Core at
the University of Philadelphia, School of Medicine. Brain
tissue of frozen globus pallidus from PSP (n = 5), CBD
(n = 4) and normal control (n = 3), was homogenized in
8m L / gh i g hs a l tb u ﬀer (HS) (weight/vol) (50mmol/L Tris,
pH 7.5, 750mmol/L NaCl, 5mmol/L EDTA; all buﬀers were
supplemented with protease inhibitor cocktail (cOmplete,
Roche Diagnostics, Mannheim, Germany) and phosphatase
inhibitors PhosSTOP (Roche Diagnostics)) and centrifuged
at 50,000 ×gf o r3 0m i n u t e sa t4 ◦C. Aliquots of the total
homogenate (TH) were taken for immunoblot analysis.
P e l l e t sw e r ee x t r a c t e dw i t h3m L / go fH Sb u ﬀer containing
1% Triton X-100 (HS-T). To remove myelin, pellets were
homogenized in 500μL HS containing 1mol/L sucrose.
Floating myelin was discarded after centrifugation. The
resulting pellets were homogenized in 2mL/g of radioim-
munoprecipitation assay (RIPA) buﬀer (50mmol/L Tris,
pH 8.0, 150mmol/L NaCl, 5mmol/L EDTA, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS)). Afterwards, pellets were extracted in 2mL/g
SDS buﬀer (62.5mmol/L Tris, pH 6.8, 1mmol/L EDTA,
0.1% β-mercaptoethanol, 2% SDS, 10% glycerol). The SDS-
insoluble pellet was further extracted by formic acid, but
did not reveal enough material for analysis. Fivefold concen-
trated sample buﬀer (312.5mmol/L Tris, pH 6.8, 5mmol/L
EDTA, 0.5% β-mercaptoethanol, 10% SDS, 50% glycerol,
0.05% bromphenol blue) was added to TH, HS, HS-T, and
RIPA, and all samples were heated to 100◦Cf o r5m i n u t e s .
Equal volumes of samples from each fraction were loaded on
7.5 and 10% polyacrylamide gels. All fractions were analyzed
by immunoblot procedure; see below. In the result section
only the TH and SDS-fractions are shown (Figure 1). α-
Tubulin of TH was used to normalize data.
2.3. Immunoblot Analysis. Cellular monolayers of control
and treated cells were washed with phosphate buﬀered
saline (PBS; 137mM NaCl, 2.7mM KCl, 1.47mM KH2PO4,
8.4mM Na2HPO4;p H7 . 4 )o n c e ,s c r a p e do ﬀ in sam-
ple buﬀer (125mM Tris, pH 6.7, 1mM EDTA, 1% β-
mercaptoethanol, 10% glycerol), containing 2% SDS, and
boiled for 10 minutes. Protein contents in the samples
were determined according to Neuhoﬀ et al. [22]. For
immunoblotting, total cellular extracts (10–20μgp r o t e i n
per lane) were separated by one-dimensional SDS-PAGE
using 7.5% or 10% polyacrylamide gels, and transferred to
nitrocellulose membranes (Schleicher and Schuell, Dassel,
Germany). The blots were saturated with TBS-T (20mM
Tris, pH 7.5, 136.8mM NaCl, 0.1%v/v Tween 20) containing
5% dry milk and incubated with the individual antibodies
overnight at 4◦C. After washing, incubation with HRP-
conjugated anti-mouse (Amersham Biosciences, Hercules,
CA, USA; 1:3000) or anti-rabbit IgG (Biorad, Munich,
Germany; 1:3000) was carried out for 1 hour, and blots
were visualized by the enhanced chemiluminescence (ECL)
procedure as described by the manufacturer (Amersham,
Braunschweig, Germany). Quantitative evaluation of the
immunoblots was carried out by densitometric scanning and
ImageQuant software (Molecular Dynamics, Sunnyvale, CA,
USA).International Journal of Cell Biology 3
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Figure 1: Biochemical analysis of tauopathy and unaﬀected control brains. (a) Representative images of total homogenate (TH) and SDS-
fractions of globus pallidus from PSP (left) and CBD (right) brains are shown. Brain tissue (1g/8 ml high salt buﬀer) was homogenized and
subjected to sequential extraction (see materials and methods). Equal amounts of samples were subjected to SDS-PAGE and immunoblot
procedure was carried out with antibodies against tau, HSP27, HSP70 and α-tubulin as indicated on the right. Co represent brain samples
of unaﬀected controls. In (b) quantitative evaluation of the HSP27 and HSP70 blots shown in (a) and (b) was carried out using ImageQuant
software. α-Tubulin from TH was used to normalize the data. Asterisk: P ≥ .05 according to t-test.4 International Journal of Cell Biology
2.4. RNA Extraction and Microarray Analysis. To study
the gene expression proﬁles total RNA was extracted of
control and PSP globus pallidus brain tissue by Miltenyi
Biotec (Cologne, Germany). Six human speciﬁc PIQOR
microarrays (Miltenyi Biotec, Cologne, Germany) consisting
of 1208 selected gene probes were used to generate an
expression proﬁle of mRNA in PSP brains versus control.
For cDNA synthesis, RNA samples of two control brains
and three PSP brains were pooled. cDNA synthesis and
puriﬁcation was carried out using the TSA-Labeling and
Detection Kit (Perkin-Elmer, USA) according to the man-
ufacturers instructions (see Perkin-Elmer, USA, Micromax
TSA Labeling and Detection Kit for kits MPS521, MPS522
for details).
Hybridization and posthybridization were carried out
usingPIQORMicroarrayKit(MiltenyiBiotec,Cologne,Ger-
many) according to the manufacturers instructions. Slides
were scanned on a microarray scanner (GenePix 4000B,
Axon Instruments, Foster City, USA). Acuity 4.0 (Molecular
Devises, Califonia, USA) was used for signal quantiﬁcation.
Signals ≤ 0.5refertounderexpressedgenes,whilesignals ≥ 2
show overexpressed genes.
2.5. Immunohistochemistry. Tissue obtained at the time of
autopsy was ﬁxed in 10% formalin, paraﬃn-embedded
and cut into 6μm thick sections. Following antigen
retrieval using Vector unmasking solution formalin-ﬁxed
brain sections were analyzed by immunohistochemistry as
described previously [23], using the avidin-biotin complex
(ABC) method (Vectastain ABC kit, Vector Laboratories,
Burlingame, CA). For double immunolabeling, sections
were blocked in 5% ChemiBLOCKER (Chemicon, Millipore,
Billerica, MA, USA) and 2% donkey serum in 0.1M Tris,
pH 7.6 supplemented with 0.1% Triton X-100 (TrisT)
overnight at room temperature after antigen retrieval. First
antibodies were diluted 1:100 in TrisT and incubated at
room temperature overnight. After 6 washes for 30 minutes
in0.1MTris,pH7.6,sectionswereincubatedwithsecondary
antibodies (1:100 in TrisT) (Jackson ImmunoResearch,
West Grove, PA, USA) overnight at room temperature.
Autoﬂuorescence was blocked as described using Sudan
Black B [24] and sections were mounted with Vectashield
mounting medium (Vector Laboratories, Burlingame, CA,
USA) containing 4 , 6-diamidino-2-phenylindole (DAPI).
Digital images of immunohistochemical preparations were
obtained using an Olympus BX 51 (Tokyo, Japan) micro-
scope equipped with bright-ﬁeld light sources with a digital
camera, the DP71 (Olympus, Orangeburg, New York), and
DP manager (Olympus). Fluorescent labelling was analysed
using a Zeiss epiﬂuorescence microscope (Oberkochen,
Germany) equipped with a digital camera using a plan-
neoﬂuar objective (100× or 40× for overview images) or a
Leica TCS SL confocal laser scanning microscope (Wetzlar,
Germany).
2.6. Primary Neuronal Cell Culture. Single cell suspensions
were prepared from cerebral hemispheres of 17-day-old
rat embryos as previously described [25]. The tissue was
homogenized in Eagles basal medium (BME), containing
0.5% heat-inactivated fetal calf serum (FCS). Cells were kept
in serum-free medium supplemented with N2-Supplement
(1:100; Invitrogen, Carlsbad, CA), L-glutamine (1:100;
Invitrogen,Carlsbad,CA),50U/mLpenicillin,and50μg/mL
streptomycin. Experiments were carried out with 7-day-old
cultures or as indicated. Twice per week, one-half of the
culture medium was exchanged.
2.7. Astrocyte Culture. Primary cultures of glial cells were
prepared from the brains of 1-2-day-old Wistar rats and
astrocytes were prepared from the ﬂasks after 6–8 days as
described previously [26]. Brieﬂy, astrocytes were trypsi-
nated from culture ﬂasks, after removal of microglia and
oligodendrocyte precursor cells, seeded on 10cm culture
dishes, and kept in DMEM supplemented with 10% fetal
calf serum (FCS). 3 days before the experiment medium was
changed to DMEM containing 0.5% FCS.
2.8. Heat Shock Treatment. Culture dishes were sealed with
paraﬁlm and immersed for 30 minutes in a water bath at
44◦C, as described before [27]. For the indicated recovery,
cells were put into the incubator. Control cells were sealed
for 30 minutes but remained in the incubator.
2.9. Oxidative Stress. Cells were treated with hydrogen
peroxide(100μM)for30minutes,themediumwasreplaced,
and cells were put into the incubator for recovery as
indicated.
2.10. Indirect Immunoﬂuorescence. Cells were cultured on
poly-L-lysine-coated glass coverslips (2.0 × 105 cells per
35mm dish) and subjected to heat shock or oxidative stress
as indicated. After washing with PBS, cells were ﬁxed with
ice-cold methanol for 7 minutes. The coverslips were washed
three times and incubated for 1 hour with anti-GFAP and
anti-α-tubulin antibodies, followed by the appropriate sec-
ondary antibodies (1:100) (Jackson ImmunoResearch, West
Grove, PA, USA), washed with PBS and mounted. Nuclei
were stained by DAPI (1.5μg/mL) included in the mounting
medium (Vectashield; Vector Laboratories, Burlingame, CA,
USA). Fluorescent labeling was studied using a Zeiss epiﬂuo-
rescencemicroscope(Oberkochen,Germany)equippedwith
a digital camera using a plan-neoﬂuar objective (100x).
3. Results
3.1. Increased Expression of Tau and HSP27 in Aﬀected
Brains of PSP and CBD Patients. Frozen tissue samples
from the globus pallidus were obtained from 5 PSP and
4 CBD patients and from 3 control cases without neu-
rological disease. The expression and solubility of tau
was determined by sequentially extracting the brain tissue
using buﬀers with increasing solubilization capabilities (see
Methods section). The individual fractions were analyzed by
immunoblot procedure using PHF-1 antibodies recognizing
hyperphosphorylated tau, and tau-1 antibodies directed
against nonphosphorylated tau, and a cocktail of t14 andInternational Journal of Cell Biology 5
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Figure 2: PIQOR microarray analysis of mRNA abundance in
PSP versus normal control brains. Six chips were generated and
statistically analyzed. Signals ≤ 0.5 (red) refer to underexpressed
genes, while signals ≥ 2 (green) show overexpressed genes. The
ﬁgure shows some genes out of 64 genes which are diﬀerentially
regulated in PSP.: TUBA: α-tubulin; DUSP1: dual speciﬁty protein
phosphatase1;PPP2R1A:serine/threonineproteinphosphatase2A;
MAL: myelin and lymphocyte protein.
t46 antibodies. Figure 1 shows the immunoblot of the total
brain homgenates (TH) and the least soluble SDS-fraction.
The majority of hyperphosphorylated tau was detected in
the SDS fraction and was present in all PSP and CBD
brain samples, although at diﬀerent levels, thus conﬁrming
the pathology (Figure 1). Brain tissue was homogenized as
weight per volume, and equal volumes of the subsequent
individual fractions were separated by SDS-PAGE. Since α-
tubulin was at approximately the same level in the TH of all
brain samples, it was used to normalize data (Figure 1(b)).
To study the expression proﬁle of genes in normal and
aﬀected brains, RNA was isolated from PSP brain tissue and
normalcontroltissue.RNAfrom3PSPand2normalcontrol
tissue samples was suitable and used for microarray analysis.
Human speciﬁc PIQOR microarrays were used to analyze
1208 genes. Quantitative analysis revealed that 38 genes were
repressedand26genesinduced,includingHSP27andHSP70
(Figure 2). The induction of HSP27 mRNA was conﬁrmed
by RT-PCR analysis using the same RNA preparations (not
shown).
This result prompted us to analyze the tissue extracts for
the presence of HSP27 and HSP70 proteins (Figure 1(a)).
Immunoblot analysis revealed that HSP27 was detectable
in all fractions of the control and aﬀected brain samples,
and in comparison to the normal controls more abundant
in the aﬀected brains. In PSP brain extracts, HSP27 was
elevated in the TH and most prominent in the least soluble
SDS-fraction, and in CBD brains HSP27 was enriched in
the TH and SDS-fraction. Also HSP70, as compared to
control nonaﬀected brain tissues, was observable at an
elevated level in the SDS-fraction of PSP and CBD brains
(Figure 1(a)).
3.2. Increased HSP27 Immunoreactivity in Aﬀected Brains.
Adjacent sections of paraﬃn-embedded globus pallidus
100μm
PHF-1 HSP27
Co
PSP
CBD
Figure 3: Expression of PHF-1 tau and HSP27 in globus pallidus
of patients with PSP and CBD in comparison to unaﬀected control
(Co). Adjacent sections were immunostained with PHF-1 (left) or
HSP27 (right). PHF-1 staining demonstrates robust tau pathology
in the aﬀected brain regions. No pathology was detected in the
brains of unaﬀected controls, while PSP and CBD brains show
characteristic glial pathology and PHF-1 positive threads.
tissue were prepared and immunostained with PHF-1 anti-
bodies, to conﬁrm tau-pathology, and antibodies against
HSP27. As compared to the normal controls, a marked
immunostaining of PHF-1 and HSP27 was observed in
the aﬀected brains (Figure 3). HSP27 staining was mainly
associatedwithcellswithastrocyticmorphologies(Figure 3).
Although PHF-1 positive coiled bodies originating in oligo-
dendrocytes were present in the brain sections of PSP and
CBD, we did not detect coiled bodies positively stained by
HSP27 in the analyzed sections. This indicates that HSP27
pathology is mainly associated with astrocytes. This was
further conﬁrmed by double immunolabelling of brain sec-
tions using antibodies against HSP27 and PHF-1 (Figure 4).
HSP27 immunoreactivity was present in numerous cells
with astrocytic morphologies. Furthermore, diﬀerences in
astrocytic pathology between PSP and CBD brain sections
wereobserved. InPSP,PHF-1 positive cellsresembling tufted
astrocytes were often also positive for HSP27 (Figure 4,P S P
patient 3). In CBD brain sections, PHF-1 positive astrocytic
plaques were seen, which in the center contained HSP27
immunoreactivity (Figure 4, CBD patient 6). Furthermore,
large astrocytes which strongly were labelled by antibodies
against HSP27 containing PHF-1 immunoreactivity in the
cellular extensions were typically observable in CBD brains
(Figure 4, CBD patient 6). The colocalization of PHF-1 and
HSP27 was further conﬁrmed by confocal microscopy. The
overlay images demonstrate that while HSP27 is mainly6 International Journal of Cell Biology
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Figure 4: Colocalization of HSP27 with tau-immunoreactive inclusions. (b) Adjacent sections from aﬀected brains, as indicated on the
left, were double labelled for HSP27 (green) and PHF-1 tau (red). HSP27 colocalizes with a subset of astrocytic pathology. In PSP (a)–
(f) astrocytic tufts positive for HSP27 and PHF-1 are seen (arrows) and in CBD (g)–(i), PHF-1 positive astrocytic plaques with HSP27 in
the center are prominent (arrows). Scale bar, 25μm. Nuclei are stained with DAPI in the overlay images. (c) Confocal overlay images of
representative cells from brain sections as depicted in (a) are shown (a,b, PSP patient 3; c, CBD patient 6). (d) Brain sections were double
labelled for HSP27 (green) and GFAP (red). All cells positively stained for HSP27 were GFAP positive, demonstrating their astrocytic origin.
Overlay images are shown for PSP patient 1 (a) and CBD patient 6 (b) and (c). Nuclei are stained with DAPI. Scale bar, 20μm.International Journal of Cell Biology 7
seen in the center of the cell throughout the cytoplasm,
PHF-1 immunoreactivity is prominent in the periphery
and the cellular extensions (Figure 4(b)). The data further
show that not all HSP27-positive cells or plaques are also
positive for PHF-1 but were colocalized in a subset of
tau-immunoreactive inclusions (Figure 4). Also, even in
brain samples with relatively little PHF-1 protein expression
as demonstrated in the immunoblots (Figure 1,P S P3
and CBD 8), HSP27 was abundantly expressed and in
a subset of cells was found in colocalization with PHF-
1. The astrocytic identity of the cells was corroborated
by double immunoﬂuorecent staining tissue sections using
antibodies against GFAP (glial ﬁbrillary acidic protein)
and HSP27. Figure 4(c) demonstrates that cells expressing
HSP27 are also positive for GFAP and thus represent
astrocytes.
3.3. Constitutive Expression and Diﬀerential Upregulation
of HSPs in Cultured Rat Brain Neurons and Astrocytes.
Previous data from our laboratory indicated that astrocytes
in comparison to oligodendrocytes derived from the brains
of newborn rats express a higher constitutive level of
the small HSPs and thus might be protected from stress
situations [18, 19]. Since tau-pathology is also prominent
in neurons, and neuronal ﬁlamentous lesions and neuropil
threads are found in PSP and CBD, we prepared cultures of
rat cerebral neurons and astrocytes to compare the pattern
of constitutively expressed HSPs. Cell extracts were subjected
toimmunoblotprocedureusingapanelofantibodiesagainst
several HSPs. Figure 5 demonstrates that astrocytes and
neurons speciﬁcally diﬀer in their abundance of the small
HSPs, that is, HSP25 and αB-crystallin, while the higher
molecular weight HSPs are similarly expressed in both cell
types.
Next we tested if neurons and astrocytes diﬀerentially
react to heat and oxidative stress. Cells were subjected
either to a heat shock (HS; 30 minutes, 44◦C, 18 hours
recovery) or to hydrogen peroxide (OS; 100μM, 30 minutes,
18 hours recovery). Immunoblot analysis reveals that HSP25
is upregulated in neurons after HS and OS, but under
no condition is as abundantly expressed as in astrocytes
(Figure 6). In neurons, αB-crystallin is inducible by HS but
not detectable after OS, while in astrocytes it is enhanced
after both stress conditions. In both cell types, HSP32 is
induced after oxidative stress and HSP70 is induced only
after heat stress, while HSP60 remains at the same level
(Figure 6). The presence and upregulation of HSP25 in
astrocytes after HS and OS was further conﬁrmed by indirect
immunoﬂuorescence using antibodies against HSP25 and
GFAP (glial ﬁbrillary acidic protein). Figure 7 demonstrates
that HSP25 is upregulated after HS and OS and distributed
in the cell body and processes and partly is associated
with glia ﬁlaments. Hence, these data show that HSPs
are diﬀerentially expressed in neurons and glia, and that
cells react to diﬀerent stress situations by upregulation of
diﬀerent stress proteins. These data underline the functional
signiﬁcance of small HSPs in glia and point to the conclusion
that cell type speciﬁc responses accompany pathological
processes.
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Figure 5: Cultured neurons and astrocytes constitutively express
heat shock proteins at diﬀerent levels. Cell lysates from astrocytes
(ASTR) and neurons at the indicated days in vitro (DIV, 3, 7,
9) were prepared and equal amounts of proteins were subjected
to immunoblot analysis using antibodies against various HSPs,
as indicated on the right. Note that in comparison to neurons
astrocytes constitutively express high amounts of HSP25 and αB-
crystallin,whileHSP60andHSC70aresimilarlyprominentinboth
cell types.
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Figure 6: Diﬀerential stress responses of neurons and astrocytes.
Neurons (7div) and astrocytes were subjected to heat shock (HS;
44◦C, 30 minutes) or oxidative stress (OS; 100μMH 2O2)a n dc e l l
lysates were prepared after a recovery period of 24 hours and equal
amounts of proteins were subjected to immunoblot analysis, using
antibodies against a variety of heat shock proteins, as indicated
on the right. Note that in both neurons and astrocytes, HSP70 is
heat-inducible, while HSP32 is only induced by oxidative stress.
Generally, the induction of HSPs after stress is more pronounced
in astrocytes than in neurons.
4. Discussion
In tauopathies such as AD, CBD, PSP, and Pick’s disease,
tau is the major constituent of intracellular inclusions, and
the fact that these can occur not only in neurons but also8 International Journal of Cell Biology
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Figure 7: Cellular distribution of HSP25 in astrocytes. Astrocytes after heat shock (HS; 44◦C, 30 minutes, 24 hours recovery) or oxidative
stress (OS; H2O2100μM, 30 minutes, 24 hours recovery) were subjected to indirect immunoﬂuorescence staining. Co: untreated control.
Double labelling was carried out using monoclonal anti-GFAP and polyclonal anti-HSP25 antibodies. Nuclei were stained with DAPI. Scale
bar = 20μm.
in astrocytes and oligodendrocytes points out that glial cells
contribute to the pathogenesis of neurodegenerative diseases
[8]. Misfolded proteins assemble and accumulate before the
onset of neurodegeneration, and it is likely that this is a
mechanism aimed at removing denatured proteins to rescue
thecells. Whenaggregatesgrow and enlarge, theymay confer
death signals and play a critical role in the pathogenesis
of the diseases. It has been suggested that various types of
inclusions may arise through common mechanisms. They
contain components of the ubiquitin proteasome system and
a variety of molecular chaperones [28]. Molecular chaper-
ones provide a ﬁrst line of defence against misfolded proteins
and closely cooperate with the proteasomal machinery
[29, 30]. HSP25/27 can confer resistance against apoptotic
stimuli and might protect the cytoskeleton during stress
[31,32].Itundergoesdynamicassemblyintolargeaggregates
and oligomerization has been suggested to be required for
chaperone function and substrate binding. The direct proof
of a chaperone function of HSP27 in vivo is still missing, but
evidence has accumulated that it contributes to an increased
chaperone activity of the cells and binds unfolded proteins,
which are then kept in a competent state to be refolded by
HSP70 [33].
Here we examined the presence of HSP27 in PSP and
CBD, representing tauopathies with abundant glial pathol-
ogy[8,12].ThedatashowthatinaﬀectedbraintissueHSP27
is enhanced in comparison to the normal control, and a large
proportion of HSP27 is only extractable with detergents
disrupting the cytoskeleton, that is, 2% SDS, similarly to
hyperphosphorylated tau. Also HSP70 is abundant in this
fraction, and microarray analysis demonstrates that mRNA
levelsencodingHSP27andHSP70areenhancedinPSPbrain
samples. Immunohistochemical data further point to the
fact that HSP27 is associated with cells displaying astrocytic
morphologies, both in PSP and CBD brains, but we could
notdetectcoiledbodiespositivelystainedforHSP27.Double
immunoﬂuorescence labelling demonstrated that not all
HSP27-positive cells displayed PHF-1 immunoreactivity, but
astrocytic tufts positive for PHF-1 and HSP27 were promi-
nent in PSP brain sections and PHF-1-positive astrocytic
plaques with HSP27 immunoreactivity in the center were
typically seen in CBD brain sections. Astrocytic tufts are
prominent features of PSP brains and astrocytic plaques are
characteristic in CBD [12]. Our data demonstrate that in
both diseases a number of cells prominently express HSP27
without displaying tau pathology. This is also the case in
brains of patients with a rather low level of PHF-1 protein
expression. This might indicate that the stress response
in astrocytes involving HSP27 upregulation precedes the
formation of tau deposits and is attempted at protecting the
cells against the protein aggregation process.
O u rd a t as u p p o r tap r e v i o u ss t u d y ,d e m o n s t r a t i n gt h a t
immunostaining for αB-crystallin and also HSP27, although
to a much lesser extent, was increased in CBD, PSP,International Journal of Cell Biology 9
and FTDP-17 [21]. αB-Crystallin staining was speciﬁcally
prominent in structures resembling coiled bodies in CBD
and FTDP-17. In the three PSP cases analyzed, which
displayed only mild tau pathology, also only mild αB-
crystallin immunoreactivity was observable [21]. HSP70
immunostaining was not increased in both aﬀected and
unaﬀected brain regions, and HSP27 immunostaining was
demonstrated predominantly in glial cells in the neocortex
of all three pathologies, but this was not further persued
biochemically in this previous study [21].
Thus, the upregulation of the small HSPs seems to be
speciﬁc for glial pathology, and implies distinct pathogenic
mechanisms for glial and neuronal cells. This is supported
by our data, demonstrating that cultured neurons and
astrocytes have a diﬀerent set or amount of constitutively
expressed HSPs and that the small HSPs, αB-crystallin
and HSP25, are speciﬁcally and prominently expressed in
unstressed astrocytes. Even after stress situations the levels of
small HSPs in neurons remain low. Similarly, oligodendro-
cytes have a low constitutive level of both small HSPs, but
respond to oxidative and proteasomal stress by prominent
induction of αB-crystallin, while HSP25 is mainly induced
after heat stress [18, 27]. Astrocytes are speciﬁcally resistant
against a variety of stress situations and our recent data
demonstratethattheyareprotectedbytheirhighconstitutive
level of HSP25 [19, 32]. Downregulation of HSP25 by siRNA
approach caused actin ﬁlament breakdown in control cells in
the absence of stress stimuli and sensitized the cells against
oxidative and proteasomal stress [19] .H e n c ec e l l - t y p ea n d
stress-speciﬁc regulation is observable in cell culture and
likely involved in disease progression.
The question remains, why small HSPs are associated
with the insoluble protein fractions of stressed cells and
aﬀected brains. Indeed, although small HSPs may prevent
protein aggregation by forming soluble complexes with
aggregation prone substrate proteins, they are often found
in insoluble detergent-resistant fractions [19, 21, 34]. Cell
culture studies have revealed that at an early state of
pathogenesis small aggregates and aggresomes are formed,
these are aimed at shielding the remaining part of the cell
body from unwanted interactions with misfolded proteins
[32, 35, 36]. In glial cells, aggresomes are formed around
the MTOC and small HSPs and ubiquitin are recruited to
the growing inclusions as a major constituent [19, 37, 38].
When cells are overloaded with nonnative substrates, small
HSPs coaggregate with nonnative proteins and are tightly
associated with and might surround inclusion bodies. This
situation is speciﬁcally promoted in stress situations, such as
oxidative stress or stress exerted by proteasomal inhibition.
To summarize, small HSPs seem to be particular impor-
tant in neurological diseases with glial pathology. They
are prominent constitutents in inclusion bodies originating
in astrocytes and oligodendrocytes. These are characteris-
tic features of CNS diseases with cytoskeletal abnormal-
ities. Although small HSPs can speciﬁcally interact with
cytoskeletal components and might preserve cell shape and
integrity, chronic overexpression, instead of protecting the
cells, might further contribute to cell damage and disease
progression.
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